OC 000459 5mg 5mg | Purity Not Available
Adooq Bioscience
OC 000459 is a potent, oral and selective CRTH2 (also known as DP2) antagonist.
More Information Supplier PageOC 000459 is a potent, oral and selective CRTH2 (also known as DP2) antagonist.
More Information Supplier PageOC 000459 is a potent, oral and selective CRTH2 (also known as DP2) antagonist.
More Information Supplier PageOC 000459 is a potent, oral and selective CRTH2 (also known as DP2) antagonist.
More Information Supplier PageAP26113 has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
More Information Supplier PageAP26113 has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
More Information Supplier PageZotarolimus is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier.
More Information Supplier PageZotarolimus is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier.
More Information Supplier PageAG-17 is an inhibitor of EGF receptor kinase with an IC50 value of 460 ??M in the human epidermoid carcinoma cell line A431.
More Information Supplier PageAG-17 is an inhibitor of EGF receptor kinase with an IC50 value of 460 ??M in the human epidermoid carcinoma cell line A431.
More Information Supplier PageAG-17 is an inhibitor of EGF receptor kinase with an IC50 value of 460 ??M in the human epidermoid carcinoma cell line A431.
More Information Supplier Page